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Abstract
Introduction: Spontaneous puberty occurs in 30% of patients with Turner Syndrome. Its absence is an indication for hormone re-
placement therapy (HRT). No reliable markers of spontaneous puberty have been defined to date.
Aim of the study: To evaluate the usefulness of antymüllerian hormone (AMH) and inhibin B assessment in predicting ovarian func-
tion and spontaneous puberty in girls with TS.
Material and methods: The study included 35 TS patients treated with human recombinant growth hormone (rhGH). Gonadal axis 
function parameters (LH, FSH and estradiol) were evaluated at the age of physiological puberty (10–12 years, mean 10.5 years), 
before introduction of HRT. Additionally AMH and inhibin B levels were assessed. In follow up patients were divided into 2 groups: 
with (SP) and without (WP) spontaneous puberty. Spontaneous puberty was defined as Tanner stage 2 or higher breast development.
Results: WP patients were observed until the mean age of 16y. SP occurred in 16 patients (mean age 10 years). Patients with SP pre-
sented with significantly lower mean FSH level (1.14–91.1 mIU/ml, mean mIU/ml 24.5 vs. 7.7–196.4 mIU/ml, mean 66.5 mIU/ml, 
p = 0.002), higher mean estradiol (10.5–68.8 pg/ml, mean 28.4 pg/ml vs. 6.1–26.0 pg/ml, mean 14.9 pg/ml, p = 0.005), AMH 
(0.0–3.11 ng/ml, mean 0.8 ng/ml vs. 0.0–0.002 ng/ml, mean 0.003 ng/ml, p = 0.001) and inhibin B (0.0–110.0 pg/ml, mean 29.1 pg/ml 
vs. 0.0–11.0 pg/ml, mean 1.06 pg/ml, p = 0.026) levels. In three SP patients without elevated FSH level (FSH < 35 mIU/ml) 
we found zero concentration levels of AMH and inhibin B. SP patients had mosaic (non 45,X) karyotype in 87.5% and WP patients 
only in 47%.
Conclusions: AMH and inhibin B assessment may be a valuable complement to the diagnosis of ovarian function in patients with TS. 
Low levels of these parameters may indicate a risk of ovarian failure even in patients with spontaneous puberty and without hyper-
gonadotropic hypogonadism.
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Streszczenie
Wprowadzenie: Samoistne dojrzewanie występuje u 30% pacjentek z zespołem Turnera (ZT), a jego brak jest wskazaniem do roz-
poczęcia hormonalnej terapii zastępczej (HRT). Dotychczas nie określono wiarygodnych markerów określających prawdopodobień-
stwo wystąpienia samoistnego dojrzewania w tej grupie pacjentek.
Cel pracy: Ocena przydatności oznaczeń stężeń hormonu antymüllerowskiego i inhibny B jako markerów czynności jajników i pre-
dyktorów wystąpienia samoistnego dojrzewania u pacjentek z ZT.
Materiał i metody: Do badania włączono 35 pacjentek z ZT leczonych ludzkim rekombinowanym hormonem wzrostu w wieku 
fizjologicznego dojrzewania płciowego (10–12 lat, średni wiek 10,5 roku). Przed wprowadzeniem HRT oceniono oś gonadalną (LH, 
FSH, estradiol). Dodatkowo oznaczono stężenie AMH i inhibiny B. Podczas obserwacji pacjentki podzielono na dwie grupy: z sa-
moistnym początkiem dojrzewania (SP) lub bez (WP). Samoistne dojrzewanie zdefiniowano jako rozwój piersi oceniony na stopień 
II lub wyższe w skali Tannera.
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Wyniki: Pacjentki z grupy WP pozostawały w obserwacji do średniego wieku 16 lat. Samoistny początek dojrzewania wystą-
pił u 16 pacjentek (średni wiek 10 lat). U pacjentek z grupy SP stwierdzono istotnie mniejsze stężenia FSH (1,14–91,1 mIU/ml, 
śr. 24,5 mIU/ml vs 7,7–196,4 mIU/ml, śr. 66,5 mIU/ml, p = 0,002), większe stężenia estradiolu (10,5–68,8 pg/ml, śr. 28,4 pg/ml vs 
6,1–26,0 pg/ml, śr. 14,9 pg/ml, p = 0,005), AMH (0,0–3,11 ng/ml, śr. 0,8 vs 0,0–0,002 ng/ml, śr. 0,003 ng/ml, p = 0,001) i inhibiny B 
(0,0–110,0 pg/ml, śr. 29,1 pg/ml vs 0,0–11,0 pg/ml, śr. 1,06 pg/ml, p = 0,026). U trzech pacjentek z grupy SP bez zwiększonego stę-
żenia FSH (FSH < 35 mIU/ml) stwierdzono zerowe stężenia AMH i inhibiny B. Kariotyp mozaikowy (nie 45,X) stwierdzono u 87,5% 
pacjentek z grupy SP i tylko u 47% pacjentek z grupy WP.
Wnioski: Ocena stężeń AMH i inhibiny B może być wnieść dodatkową wartość podczas oceny funkcji jajników u pacjentek z ZT. 
Małe stężenia tych markerów mogą wskazywać na ryzyko niewydolności jajników nawet u pacjentek, które rozpoczęły dojrzewanie 
samoistnie i u których nie stwierdzono hipogonadyzmu hipergonadotropowego.
Słowa kluczowe: 
zespół Turnera, hipogonadyzm, dojrzewanie, AMH, inhibina B.
Introduction 
Primary ovarian insufficiency means diminished functional 
activity of ovaries when defect is inherent within the gonads. 
One of the chromosomal abnormalities which is characterized 
by primary ovarian failure is Turner syndrome (TS). Although 
TS is in most patients associated with pubertal delay or failure 
and infertility, hypogonadism may occur at different age and 
clinically manifest as late or absent puberty, primary or sec-
ondary amenorrhea [1, 2]. According to literature up to 30% of 
TS patients present with spontaneous pubertal development, 
2–5% have regular menstrual cycles and 2% may get preg-
nant spontaneously [3]. As an ovarian insufficiency in TS pa-
tients is caused by accelerated loss of follicles that may start 
already into fetal life, it is important to identify right patients 
and time point for potential cryopreservation of ovarian tissue 
before follicles begin to disappear [4–6]. Moreover, estrogens 
are secreted from the healthy ovaries already in the prepubertal 
period and they seem to improve cognition and bone mineral 
density, optimize response to growth hormone treatment and 
bring some beneficial metabolic effect [7–14]. Gonadal axis in 
prepubertal children with ZT is difficult to be diagnosed, be-
cause it is centrally inhibited [15]. In that age, there is an over-
lap of the gonadotropin levels values between healthy girls and 
TS patients, therefore they may not reflect ovarian reserve in 
this period of life [15–17]. Some authors tried to define cut off 
value of serum FSH concentration in prepubertal girls with TS 
as an index for predicting spontaneous puberty and menarche, 
but to date there are no concrete guidelines in this field [18, 19]. 
To date no reliable markers of spontaneous puberty have been 
defined. Novel candidates for ovarian function markers in TS 
patients are: Antymüllerian hormone (AMH) and inhibin B, that 
are secreted from developing follicles and have been found to 
positively correlate with antral follicle count [20]. It is believed 
that serum AMH and inhibin B levels reflects ovarian reserve in-
dependent from the hypothalamo-pituitary-gonadal axis. More-
over the decline in serum AMH levels precedes the changes 
in another markers for ovarian reserve (FSH, estradiol and in-
hibin B) [21, 22]. 
Aim
The present study aimed to evaluate the usefulness of AMH 
and inhibin B assessment in predicting ovarian function and 
spontaneous puberty in patients with TS.
Material and methods
The study conducted in the Department of Pediatric and 
Adolescent Endocrinology in Children’s University Hospital in 
Krakow included 35 girls with TS (12 with monosomic karyo-
type [45,X] and 23 with non-monosomic karyotype [non 45, X]) 
treated with rhGH. Evaluation of gonadal axis function was 
performed at the age of physiological puberty (10–12 years, 
mean 10.5 years), before introduction of hormonal replacement 
therapy (HRT). Additionally AMH and inhibin B levels were as-
sessed. In follow up patients were divided into 2 groups: with 
spontaneous puberty (SP) and without (WP). Spontaneous pu-
berty was defined as Tanner stage 2 or higher breast devel-
opment. In patients without spontaneous puberty induction of 
puberty using oral estrogen (Estrofem mite Novo Nordisk pills 
containing 1 mg of 17β-estradiol) was started in accordance 
with present standards after the age of 12.
Serum FSH and LH levels were measured by chemilumi-
nometric assay with an ADVIA CENTAUR XPT machine. Serum 
estradiol was measured with radioimmunoassay. Serum AMH 
was measured by electrochemiluminescence immunoassay 
(ECLIA) with a  COBAS machine. Serum Inhibin B was mea-
sured by enzyme-linked immunosorbent assay (ELISA) with an 
EUROIMMUN analyzer. Karyotypes results were obtained from 
patients records. All karyotyping analysis was performed using 
lymphocyte cultures.
To compare the two sets of data, the Student’s t test or two-
sided Mann–Whitney U test was used. For a correlation analysis, 
the correlation coefficient (R) and regression analysis were used. 
The purpose of determining the odds ratio (OR) was to use the 
logistic regression analysis. Statistically significant results were 
assumed for which the probability value was less than 0.05.
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Results
Patients without spontaneous puberty were observed un-
til the mean age of 16 years. Spontaneous puberty occurred 
in 16 patients at the mean age of 10 years (9–12 years old). 
Patients with SP presented with significantly lower mean 
FSH level (1.14–91.1 mIU/ml, mean value 24.5 mIU/ml vs. 
7.7–196.4  mIU/ml, mean value 66.5 mIU/ml, p  =  0.002), 
significantly higher mean estradiol (10.5–68.8 pg/ml, mean 
value 28.4 pg/ml vs. 6.1–26.0 pg/ml, mean value 14.9 pg/ml, 
p  =  0.005), AMH (0.0–3.11  ng/ml, mean value 0.8 ng/ml 
vs. 0.0–0.002 ng/ml, mean value 0.003 ng/ml, p  =  0.001) 
and inhibin B (0.0–110.0  pg/ml, mean value 29.1 pg/ml vs. 
0.0–11.0 pg/ml, mean value 1.06 pg/ml, p = 0.026) levels. In-
terestingly, in three SP patients with not elevated FSH level 
(FSH < 35 mIU/ml) we found zero concentration levels of AMH 
and inhibin B. Patients with SP had mosaic (non 45, X) karyo-
type in 87.5% (14/16) and monosomy (45, X) only in 12.5% 
(2/16). Patients without spontaneous puberty had mosaic (non 
45, X) karyotype in 47 % (9/19) and monosomy in 53% (10/19).
Discussion
Primary hypogonadism is stated as one of the main fea-
tures of TS. Although most patients demand estrogen replace-
ment therapy, secretion of endogenous estrogens may be suffi-
cient in some patients to finish the process of puberty, maintain 
menstrual cycles and even lead to not assisted pregnancy [3]. 
In our study 45% of TS patients presented with spontane-
ous puberty before the age of 12. Our results remain in accor-
dance with another studies with the frequency of spontaneous 
puberty in TS patients of about 50% [4, 19]. In contrast there 
are also authors noticing lower percentage of spontaneous pu-
berty in this group of patients [23–25]. Undoubtedly recogni-
tion of non-full-blown forms of TS will be growing thanks to the 
availability of karyotyping, so it may reveal noticeably increased 
prevalence of spontaneous puberty.
Correlation between karyotype and ovarian function in TS 
patients has been widely discussed and many authors stated 
that monosomic TS patients (45,X) are less likely to develop 
spontaneous puberty than patients with non-45,X karyotype 
[4, 15, 19, 21, 23]. Also in our study we observed that patients 
with non-monosomic karyotype are more likely to start puberty 
spontaneously than monosomic ones (14/23 61% vs. 2/12 
16%). Nevertheless, definitive prediction of the occurrence of 
spontaneous puberty on the basis of karyotype is not pos-
sible. Therefore, there is no reason to wait longer than until 
11–12 years of age for the first symptoms of puberty in non-45, 
X karyotype TS girls [19]. 
Diagnosis of hypergonadotropic hypogonadism in adult 
post-menstrual women is defined as FSH level above 40 µIU/ml. 
In prepubertal children there are no specific guidelines for pre-
dicting hypogonadism, although some authors suggested limit 
of FSH (6.7 mIU/ml and 10 mIU/ml respectively) above which 
spontaneous puberty is less probable [18, 19]. 
In big cross-sectional study Visser et al. found negative cor-
relation between FSH and AMH as well as between LH and 
AMH. For the subgroup of girls before the age of 12 with FSH 
level > 10 mIU/ml the odds of measurable AMH was 19 times 
lower. Strong relationship was observed for measurable serum 
AMH and signs of spontaneous puberty [4]. The chance of 
spontaneous pubertal onset was increased 19 times if AMH 
was detectable [4]. It was also showed by Lunding et al. that 
any of girls with AMH < 4 pmol/l entered puberty spontaneously 
[26]. In Hagen’s et al. [15] longitudinal study ovarian failure was 
predicted in all patients with exclusively undetectable inhibin B. 
 In our study we also found significantly lower concentration 
of FSH and higher AMH and inhibin B levels in patients with 
spontaneous puberty. Interestingly in three SP patients without 
elevated FSH AMH and inhibin B concentrations were zero. 
This stays in compliance with Hagen’s and Kalsey’s observa-
tions that decline in serum AMH levels precedes the changes 
in another markers for ovarian reserve (FSH, estradiol and in-
hibin B) [21, 22].
Limitation of our study may be observation, that 37% of 
healthy girls have undetectable inhibin B levels [27]. Another 
weak point of our study may be also the fact that we used cut-
off age of 12 when about 75–90% of TS girls enter puberty. 
At this age, according to the present guidelines induction of 
puberty is usually started. Nevertheless, some of the patients 
might enter spontaneous puberty later [28–31]. Also about 50% 
of TS patents who entered puberty spontaneously would not be 
able to complete puberty so longitudinal monitoring of puberty 
and AMH and Inhibin B levels would be needed [32]. What is 
more in our study we did not differentiate patients according 
to growth hormone treatment whilst Visser et al. claimed that 
GH therapy increases the odds of having measurable AMH in 
TS so this aspect also needs further examination [4]. 
Despite these limitations, results of the study provide next 
argument supporting consideration of monitoring AMH and in-
hibin B levels to predict spontaneous puberty in TS patients 
and start estrogen replacement in most suitable moment. Fur-
ther investigations in this field are needed for development of 
better standards of comprehensive care for patients with TS.
Conclusions
AMH and inhibin B assessment may be a valuable comple-
ment to the diagnosis of ovarian function in patients with TS. 
Low levels of these parameters may indicate a risk of ovarian 
failure even in patients with spontaneous puberty and without 
hypergonadotropic hypogonadism. 
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